This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martin, R. C.G. Articles by Cody III, H. S. Search for Related Content PubMed PubMed Citation Articles by Martin, R. C.G. Articles by Cody III, H. S. Related Collections Sentinel lymph node

Highest Isotope Count Does Not Predict Sentinel Node Positivity in All Breast Cancer Patients

From The Breast Service, Department of Surgery (RCGM, JF, PIB, HSC) and the Department of Nuclear Medicine (HY), Memorial Sloan-Kettering Cancer Center, New York, New York.

Correspondence: Address correspondence and reprint requests to: Hiram S. Cody III, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; Fax: 212-794-5812; E-mail: codyh{at}mskcc.org

Background: Radioisotope mapping is an essential technical component of sentinel lymph node (SLN) biopsy, and most authors define isotope success by an arbitrary threshold SLN-to-background ratio. Few studies have examined the degree to which the relative level of SLN counts correlates with the presence of metastasis. Having removed the SLN with the highest counts, how far should the surgeon persist in removing additional SLN which contain much lower levels of isotope?

Methods: We performed SLN biopsy, using both radioisotope and blue dye, in 2285 consecutive patients with stage I-II breast cancer. Successful isotope localization was defined as an ex vivo SLN-to-axillary background count ratio of at least 4:1, and enhanced pathologic analysis (serial sections and immunohistochemistry) was used throughout.

Results: Among the 1566 patients with more than one SLN site identified, the SLN contained metastasis in 463 (30%). In 369 (80%) of these SLN-positive cases, the SLN with the highest count contained tumor, but in 94 (20%) it was benign. Among these 94: (1) the counts of the hottest benign SLN exceeded those of the histologically positive SLN by a ratio of at least 10:1 in 31% (29 of 94) of cases, (2) the counts of the positive SLN were < 4:1 those of the axillary background in 16% (15 of 94) of cases, and (3) blue dye failed to identify 27% of positive SLN. No optimum ratio of SLN-to-SLN or SLN-to-background counts identified the positive SLN in all cases.

Conclusion: Although the SLN with the highest counts is positive in 80% of breast cancer patients with multiple SLN, neither a relatively high isotope count nor the presence of blue dye consistently predict SLN positivity in all breast cancer patients. For maximum accuracy, SLN biopsy requires (1) the removal of all nodes containing isotope regardless of the relative magnitude of counts, (2) the concurrent use of blue dye to salvage those procedures in which isotope fails, and (3) the removal of all clinically suspicious non-SLN.

Key Words: Sentinel node biopsy • Breast cancer • Lymph node metastasis • Lymphoscintigraphy

This article has been cited by other articles:

				M. C. van Rijk, E. E. Deurloo, O. E. Nieweg, K. G. A. Gilhuijs, J. L. Peterse, E. J. T. Rutgers, R. Kroger, and B. B. R. Kroon Ultrasonography and Fine-Needle Aspiration Cytology Can Spare Breast Cancer Patients Unnecessary Sentinel Lymph Node Biopsy Ann. Surg. Oncol., January 1, 2006; 13(1): 31 - 35. [Abstract] [Full Text] [PDF]

				J.-M. Classe, M. Fiche, C. Rousseau, C. Sagan, F. Dravet, R. Pioud, A. Lisbona, L. Ferrer, L. Campion, I. Resche, et al. Prospective Comparison of 3 {gamma}-Probes for Sentinel Lymph Node Detection in 200 Breast Cancer Patients J. Nucl. Med., March 1, 2005; 46(3): 395 - 399. [Abstract] [Full Text] [PDF]

				O. E. Nieweg and S. H. Estourgie What is a Sentinel Node and What is a False-Negative Sentinel Node? Ann. Surg. Oncol., March 1, 2004; 11(3_suppl): 169S - 173S. [Abstract] [Full Text] [PDF]

				K. Suga, Y. Yuan, M. Okada, N. Matsunaga, A. Tangoku, S. Yamamoto, and M. Oka Breast Sentinel Lymph Node Mapping at CT Lymphography with Iopamidol: Preliminary Experience Radiology, February 1, 2004; 230(2): 543 - 552. [Abstract] [Full Text] [PDF]

				M. L. Quan, D. McCready, W. J. Temple, and J. G. McKinnon Biology of Lymphatic Metastases in Breast Cancer: Lessons Learned From Sentinel Node Biopsy Ann. Surg. Oncol., June 1, 2002; 9(5): 467 - 471. [Abstract] [Full Text] [PDF]

				K. M. McMasters, S. L. Wong, and C. Chao Comment on the article "Highest Isotope Count Does Not Predict Sentinel Node Positivity in All Breast Cancer Patients," by Martin et al., August 2001, Annals of Surgical Oncology Ann. Surg. Oncol., April 1, 2002; 9(3): 317 - 318. [Full Text] [PDF]